Epidemiological Study to Evaluate the Prevalence and Progression of Diabetic Macular Ischemia in Patients with Diabetic Retinopathy Treated with Panretinal Photocoagulatio
Not Applicable
- Conditions
- Diabetic Macular Ischemia
- Registration Number
- JPRN-UMIN000042801
- Lead Sponsor
- Boehringer Ingelheim International GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 539
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria (Part A and B): Patients currently participating in an interventional trial with an ophthalmologic experimental therapy Exclusion criteria (Part B only): Severe DRIL, i.e., affecting 50% or more of the central one-mm-wide zone centered on the fovea (foveal DRIL), as defined by Sun et al. [R19-4048]* Any concurrent macular abnormality other than DMI and DME that, in the opinion of the investigator, would interfere with the assessment of DMI and DME (e.g., significant macular epiretinal membrane, neovascular age-related macular degeneration, and macular hemorrhage)*
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method